Allergan issues an urgent device recall for the XEN® Glaucoma Treatment System (XEN® 45 Gel Stent)

Allergan plc (NYSE: AGN) announced a voluntary recall of its XEN 45 glaucoma drainage device after a small number of units in an unreleased lot were observed to have trace amounts of polishing compounds that are used in the needle sleeve manufacturing process, according to a joint news release with ASCRS.  Allergan stated that it has engaged regulatory agencies and is initiating a voluntary recall of affected lots of XEN 45.

 

According to the company, the “XEN® Gel Stent” is a surgical implant designed to lower high eye pressure in open-angle glaucoma patients where previous surgical treatment has failed and/or medications alone were insufficient (also known as refractory glaucoma).  The device is marketed for the surgical management of refractory glaucomas, including cases where previous surgical treatment did not work, cases of primary open-angle glaucoma, and cases of pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy.  In a letter dated on October 30th, 2019, Allergan issued communication to customers, and through the company website, stated that fifteen (15) lots of XEN® Glaucoma Treatment System are to be recalled.  Allergan also advised the U.S. Food and Drug Administration of the voluntary recall.

 

According to information from the company, an inspection found 4 (four) units in an unreleased XEN® 45 lot observed to have trace amounts of residual polishing compounds used in the needle sleeve manufacturing process. The device had been shipped with the product since January 19th, 2017.  Allergan advised that “the residual polishing compounds on the XEN® injector needle assembly could transfer to the patient’s eye during procedure possibly resulting in irritation, inflammation, local allergic reaction/ hypersensitivity, iritis, uveitis/sterile endophthalmitis or an intraocular foreign body. Signal detection review does not indicate an adverse trend associated with the residual polishing compounds”.  An additional statement from Allergan said, “physicians are advised to continue routine post-operative follow up and report any adverse events to Allergan Product Surveillance at 1 (800) 433-8871. Allergan regrets any inconvenience this causes for you or your patients and appreciate your understanding as it works to resolve this issue swiftly and completely.”

12 thoughts on “Allergan issues an urgent device recall for the XEN® Glaucoma Treatment System (XEN® 45 Gel Stent)”

  1. I simply couldn’t leave your website prior to suggesting that I actually enjoyed the usual info
    a person provide for your visitors? Is gonna be again frequently in order to check out new posts

  2. I love your blog.. very nice colors & theme. Did you create this website yourself or did you
    hire someone to do it for you? Plz respond as I’m looking to create my own blog and
    would like to find out where u got this from.
    many thanks

  3. I just want to say I am just new to blogging and site-building and honestly loved you’re web page. Very likely I’m want to bookmark your blog . You actually have awesome article content. Cheers for sharing with us your blog site.

  4. I simply want to tell you that I am beginner to blogs and seriously enjoyed you’re web-site. Likely I’m want to bookmark your blog . You actually come with excellent posts. Regards for sharing with us your web site.

  5. When I originally commented I clicked the -Inform me when brand-new remarks are included- checkbox as well as now each time a remark is included I obtain 4 e-mails with the very same remark. Exists any way you can remove me from that solution? Many thanks!

  6. Nice post. I learn something more challenging on distinct blogs everyday. It will always be stimulating to read content off their writers and practice a little something from their store. I’d choose to use some with all the content in my small weblog whether you do not mind. Natually I’ll provide a link on your own internet weblog. Many thanks sharing.

Leave a Reply

Your email address will not be published.